The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus

Early Phase 1

Completed

Conditions: Short Segment Barrett's Esophagus
Long Segment Barrett's Esophagus

Interventions: Drug: Omeprazole
Drug: Vitamin D3
Procedure: upper endoscopy
Drug: Metformin

First Posted Date: 2011-11-04

Last Posted Date: 2016-03-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT01465113

Locations: 🇺🇸
University Hospitals Ahuja Medical Center, Beachwood, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Not Applicable

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma

Interventions: Drug: plerixafor
Biological: filgrastim
Drug: etoposide
Procedure: leukapheresis

First Posted Date: 2011-08-03

Last Posted Date: 2019-06-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01408043

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Early Phase 1

Withdrawn

Conditions: Stage I Colon Cancer
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage I Rectal Cancer

Interventions: Dietary Supplement: cholecalciferol
Procedure: biopsy
Genetic: protein expression analysis
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis
Genetic: reverse transcriptase-polymerase chain reaction

First Posted Date: 2011-07-27

Last Posted Date: 2014-01-17

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01403103

Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)

Phase 1

Terminated

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction

Interventions: Drug: Carboplatin AUC
Drug: Paclitaxel
Drug: lapatinib

First Posted Date: 2011-07-15

Last Posted Date: 2019-03-19

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT01395537

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Dietary Supplement: defined green tea catechin extract
Other: placebo
Other: immunohistochemistry staining method
Other: immunoenzyme technique
Other: questionnaire administration
Procedure: therapeutic conventional surgery
Other: high performance liquid chromatography
Other: mass spectrometry

First Posted Date: 2011-04-22

Last Posted Date: 2012-03-15

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT01340599

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Early Phase 1

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Nexavar

First Posted Date: 2011-04-19

Last Posted Date: 2012-03-21

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 2

Registration Number: NCT01337492

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Phase 3

Terminated

Conditions: Refractory Multiple Myeloma

Interventions: Biological: filgrastim
Drug: plerixafor

First Posted Date: 2011-02-23

Last Posted Date: 2014-08-06

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT01301963

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant

Phase 2

Withdrawn

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Radiation: stereotactic body radiation therapy

First Posted Date: 2010-09-02

Last Posted Date: 2012-04-18

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01194206

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Phase 2

Terminated

Conditions: Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Oropharynx
Stage IV Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Verrucous Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage IV Verrucous Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Drug: erlotinib hydrochloride
Radiation: intensity-modulated radiation therapy
Other: pharmacogenomic studies
Other: gene expression analysis
Radiation: 3-dimensional conformal radiation therapy
Other: biopsy
Other: pharmacological study
Other: laboratory biomarker analysis
Other: questionnaire administration
Other: enzyme-linked immunosorbent assay
Other: polymorphism analysis

First Posted Date: 2010-09-01

Last Posted Date: 2020-05-12

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 2

Registration Number: NCT01192815

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: busulfan
Drug: cyclophosphamide
Procedure: allogeneic bone marrow transplantation
Drug: methylprednisolone
Drug: methotrexate
Drug: cyclosporine

First Posted Date: 2010-08-09

Last Posted Date: 2010-08-09

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT01177371

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Home Terms & Conditions Privacy Policy